Anthropic Acquires Biotech AI Startup Coefficient Bio for $400M

Quick Facts

• Anthropic bought Coefficient Bio for $400 million in an all-stock transaction
• The 10-person startup was founded by former Genentech scientists Samuel Stanton and Nathan Frey
• The deal follows Anthropic’s $30 billion Series G funding round and $380 billion valuation in February

Anthropic acquired stealth biotech AI startup Coefficient Bio in a $400 million all-stock deal, marking the AI company’s largest expansion into healthcare and life sciences.

The acquisition brings a team of about 10 people to Anthropic’s health and life sciences division, led by Eric Kauderer-Abrams. Coefficient Bio was founded eight months ago by Samuel Stanton and Nathan Frey, both former scientists at Genentech’s Prescient Design unit.

Nathan Frey served as Group Leader and Principal Scientist at Prescient Design, where he led teams working on biological foundation models and AI approaches to drug design. He was part of Roche and Genentech’s Foundation Model and Large Molecule Drug Discovery Leadership Teams.

“We’re ushering biopharma into the Intelligence Age. It will change everything about how the industry learns and makes decisions,” Stanton tweeted in January while recruiting talent.

The deal comes after Anthropic’s massive funding success. In February, the company completed a $30 billion Series G round at a $380 billion post-money valuation, jumping from its previous $183 billion valuation. Anthropic reported reaching a $14 billion annual revenue run rate in less than three years.

Coefficient Bio developed an AI platform for drug discovery and biological research, focusing on research planning, clinical regulatory strategy, and identifying new drug opportunities. The startup was half-owned by venture capital firm Dimension, which reported a 38,513% IRR on the investment.

The acquisition aligns with broader industry trends. The AI drug discovery market is projected to grow from $1.5 billion to approximately $13 billion by 2032. Some estimates suggest generative AI could deliver $60-110 billion in annual value for pharmaceuticals overall.

“The same capabilities that make Claude exceptional for coding are also unlocking other new categories of work: financial and data analysis, sales, cybersecurity, scientific discovery, and beyond,” Anthropic said in its February press release.

Against Anthropic’s $380 billion valuation, the $400 million acquisition represents roughly 0.1% dilution. The stock-based transaction structure suggests confidence in the company’s long-term valuation trajectory as it prepares for a widely anticipated IPO.

The deal contrasts with rival OpenAI’s recent media-focused acquisition, highlighting different strategic approaches among leading AI companies.

Read more: Anthropic buys biotech startup Coefficient Bio in $400M deal: Reports